Rheumatic Causes for Fever of Unknown Origin Fever of unknown origin (FUO) represents a diagnostic challenge to many physicians and while cancer and infectious causes need to be excluded, rheumatic disorders are amongst the most common causes of FUO. https://t.co/2tlibH3SHO https://t.co/QsmkfeGEvb

• https://bit.ly/3cRtMpO

Physician Assistant Salaries -Amer Academy of Physician Assoc 2022 Report Critical care $122,832 Emer Med $121,480 Surgery $121,400 Cardiology $118,000 Heme/Onc $117,297 Rheumatology $113,000 ID $113,000 GI $113,000 Pulm $112,900 PCP $112,000 https://t.co/14SafbtTGm https://t.co/1yuPI5pAYE

• https://bit.ly/3Qagvab

The FDA has extended its indications for ustekinumab (Stelara) for use in pediatric psoriatic arthritis aged 6 years and older. Pediatric PsA makes up 6% of all pediatric inflammatory arthritis pts. https://t.co/vTM4x53n7k https://t.co/aQcuMury2k

• https://prn.to/3bhRTha

FDA has approved a topical PDE4 inhibitor Roflumilast (Zoryve) a 0.3% cream for use in Plaque Psoriasis (Age 12 and Older) https://t.co/qDuCgUwmZV https://t.co/c0a7723A1X https://t.co/v5T66iKnvc

• https://bit.ly/3PSzCpt
• https://bit.ly/3JphbpZ

THe microbiome differs between #AS (n 33) and AS-IBD(59) compared to IBD (105) patients. Study comparing feces & intesting Bx. Microbiome composition correlated with BASDAI and faecal calprotectin (FCP) levels. https://t.co/D4QCVVDK7G https://t.co/OJkeisycg0

• https://bit.ly/3PU6bUe

Review of Clinical Trial measures in systemic sclerosis: -RCTs focus on skin dz, ILD or Pulm HTN using mod. Rodnan skin (MRSS), 6-min walk -FVC is surrogate measure for SSc-ILD - Composites: CRISS, the EUSTAR-AI -Future: Skin mRNA biomarkersTHBS1 and COMP https://t.co/KPLiNTSSZA https://t.co/YgvWuMiU4i

• https://go.nature.com/3zGmTRe

Heterozygous deficiency of Aggrecan (proteoglycan w/in cartilage) gene: manifests as inherited short stature, early-onset osteoarthritis, degenerative disc disease, osteochondritis dissecans, increasing joint pathology over time https://t.co/dQERowhrba https://t.co/q7a38FGEzb https://t.co/TPQmnGPoDw

• https://bit.ly/3S7FjSd
• https://bit.ly/3zHGqk1

Belimumab (Benlysta) has been FDA approved for use in pediatric patients with active lupus nephritis who are receiving standard lupus therapy. The approval in kids is for the IV formulation only; SC belimumab is for SLE and LN in adults https://t.co/TKyNDwIUQH https://t.co/6VaMOMfwYi

• https://bit.ly/3OLmpgP

Metanalysis of cardiovascular effects of Colchicine: 21 RCTs (15,569 pts shows colchicine was superior to placebo reducing CV events; with lower risk recurrent pericarditis (RR 0.50), MACE (RR 0.67), & AFib recurrence (RR 0.68) https://t.co/hksDaCSj02 https://t.co/eGRVqZiBBx

• https://bit.ly/3POgF7i

Nintedinib’s Durable Efficacy in Systemic Sclerosis Patients with interstitial lung disease (ILD) related to systemic sclerosis continued to see less progression when treated with nintedanib (Ofev) in the pivotal 100-week SENSCIS trial, researchers said. https://t.co/5M92Yhpeo1 https://t.co/qZvwfLs1jx

• https://bit.ly/3oCjUTA

EMA in Europe has approved Rinvoq (upadacitinib 45 mg and 15 mg and 30 mg) for the treatment of adult patients with moderately to severely active ulcerative colitis who are DMARD-IR or biologic-IR. Based on 3 phase III trials. https://t.co/CbRQGzxJEr https://t.co/SlJNprUay3

• https://bit.ly/3PMMQ7i

New podcast—Dr.Cush answers your questions! https://t.co/cif6yo0tGi https://t.co/kia5J0OMf6

• https://bit.ly/3zhwtIH

Japanese SLE registry looked at infection risk with Prednisolone (PSL). Among 509 SLE pts (47 yrs); 77% used immunosuppressants & 52 had hospitalized infxns. Signif higher SIE w/ PSL 5.0–7.5 mg (aHR 6.8) & PSL 7.6-15 mg (aHR 7.6) vs 0-2.5 mg/d https://t.co/xZ5Yx4X1uw https://t.co/FSfsTENeUx

• https://bit.ly/3bcstkV